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The human body develops from a single cell, the zygote, the product of the maternal
oocyte and the paternal spermatozoon. That 1-cell zygote embryo will divide and
eventually grow into an adult human which is comprised of ∼3.7 × 1013 cells. The
tens of trillions of cells in the adult human can be classified into approximately 200
different highly specialized cell types that make up all of the different tissues and organs
of the human body. Regenerative medicine aims to replace or restore dysfunctional cells,
tissues and organs with fully functional ones. One area receiving attention is regeneration
of the intervertebral discs (IVDs), which are located between the vertebrae and function
to give flexibility and support load to the spine. Degenerated discs are a major cause
of lower back pain. Different stem cell based regenerative medicine approaches to
cure disc degeneration are now available, including using autologous mesenchymal
stem cells (MSCs), induced pluripotent stem cells (iPSCs) and even attempts at direct
transdifferentiation of somatic cells. Here we discuss some of the recent advances,
successes, drawbacks, and the failures of the above-mentioned approaches.
Keywords: stem cell, pluripotency, regenerative medicine, differentiation, intervertebral disc, lower back pain,
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HUMAN STEM CELL TOTIPOTENCY
The most stringent definition of human totipotency is defined as the ability of a single cell when
placed in its normal environment (i.e., uterus) to undergo a developmental program that eventually
gives rise to an offspring which itself is fertile (Condic, 2014). In human embryos experimental
evidence indicates that the cells of the embryo are totipotent from the 1-cell stage (zygote) up until
the 4-cell stage, where it has been shown that at least one of the blastomeres of the 4-cell embryo
(after reimplantation into the uterus) is capable of giving rise to a fertile human (Veiga et al., 1987;
Van De Velde et al., 2008; De Paepe et al., 2014). It has been suggested that the blastomeres of
the 8-cell embryo are also totipotent as individual blastomeres are able to give rise to both the
inner cell mass (ICM) and trophectoderm (TE) of the blastocyst (Mottla et al., 1995). Furthermore,
molecular studies have shown that the transcriptomes of individual blastomeres taken from 8-cell
embryos are essentially identical, suggesting that they have yet to make any molecular decisions
regarding lineage commitment or differentiation (Galan et al., 2010). But using the strict definition
of totipotency as described above, evidence is lacking that the individual blastomeres of the 8-cell
human embryo are indeed totipotent.
Kraus and Lufkin Stem Cells and Intervertebral Disk Degeneration
PLURIPOTENCY
It has been estimated that the human body is made up of
∼3.7 × 1013 cells (Bianconi et al., 2013) and by histological
analysis these cells are commonly divided into ∼200 different
cells types (reviewed in Alberts et al., 2015). The developmental
potency of in vitro established human cell lines isolated
from preimplantation stage human embryos has been studied
intensively over the past several years. The earliest developmental
stage of human embryonic stem cells (hESCs) isolated in vitro
are referred to as “naïve” (meaning of greater developmental
potential) and subsequently transitions through to a stage of
lesser potential termed “primed” (reviewed in Nichols and
Smith, 2009; Davidson et al., 2015; Ávila-González et al., 2016;
Hockemeyer and Jaenisch, 2016; Weinberger et al., 2016; Wu
et al., 2016 and references therein). Cells of the primed stage
are equivalent to epiblast cells of the preimplantation human
embryo. Epiblast cells are capable of giving rise to the each of the
three principal germ layers, ectoderm, mesoderm, and endoderm
of the embryo. The mesodermal layer is what gives rise to the
notochord and somites, the two precursors which eventually
give rise to the cells of the nucleus pulposus (NP) and annulus
fibrosus (AF), respectively, of the intervertebral disc (reviewed in
Sivakamasundari and Lufkin, 2012, 2013).
MULTIPOTENT MESENCHYMAL STEM
CELL
Mesenchymal stem cells (MSCs) are termed “multipotent” as
they were initially shown to be able to differentiate into
three different lineages, namely adipocytes, osteoblasts, and
chondrocytes (Pittenger et al., 1999). MSCs were initially found
in adipose tissue, dental pulp, bone marrow, and circulating
blood. Recent advances withMSCs have shown they also have the
ability to differentiate into myocytes, cardiomyocytes, fibroblasts,
myofibroblasts, epithelial cells, and neurons (reviewed in Liu
et al., 2009) and can be found in other hematopoietic sites such
as fetal cord blood and liver. Recent studies indicate an even
greater number of tissues which contain MSCs (Perez-Silos et al.,
2016). Given the larger number of cell types which the MSCs are
capable of differentiating into, and the different germ layers from
which these differentiated cells are normally derived, it might
be more appropriate to consider them pluripotent rather than
only multipotent. Additionally MSCs are phenotypically quite
heterogeneous, so current criteria for what constitutes a MSC is
that it must: (1) adhere to plastic cell culture dishes; (2) express
certain CD markers in the majority (95%) of the population
(CD105, CD90 and CD73) and not express a group of six CD
markers as well as HLA-DR in the same population and; (3) be
able to differentiate into adipocytes, osteoblasts and chondrocytes
(reviewed in Liu et al., 2009).
WHY IS THE INTERVERTEBRAL DISC
IMPORTANT?
The vertebral column is the most critical physical support
framework for vertebrates, functioning to provide mechanical
support along with flexibility, as well as protection of the spinal
cord and associated spinal nerves (Figure 1). The vertebral
column is comprised of a characteristic metameric arrangement
of the vertebral bodies linked together by intervertebral
discs (reviewed in Sivakamasundari and Lufkin, 2012, 2013;
Lawson and Harfe, 2015). An indispensable aspect of the
vertebral design, the intervertebral disc (IVD) serves to
withstand biomechanical forces and confers tensile strength
and flexibility in motion to an otherwise rigid spine (Risbud
and Shapiro, 2011). Intervertebral disc degeneration is a
prevalent spinal malady, which can lead to back pain, as
can more severe spine aﬄictions like spinal stenosis, IVD
herniation, or radiculopathy. At some point in their lives,
over 75% of the population will be affected by low back pain
(Raj, 2008). In the USA the annual expenditures related to
chronic back pain can surpass $35 billion in terms of medical
health care costs and the reduction in productivity from lost
workdays. This exceeds the combined costs of coronary artery
disease, stroke, rheumatoid disease, diabetes, and respiratory
infection and imposes an enormous socio-economic burden
(Walker, 2000; Goetzel et al., 2003; Katz, 2006).
DEVELOPMENTAL BIOLOGY OF THE
INTERVERTEBRAL DISC
The IVD is an unique non-vascularized fibrocartilage tissue
consisting of a lamellar-structured circular AF surrounding
the central NP core and incased above (superior) and below
(inferior) by the vascularized cartilage endplates through which
nutrients can diffuse to the AF and NP (Sivakamasundari
and Lufkin, 2012; Kraus and Lufkin, 2016). The IVD is the
largest non-vascularized tissue in the body. The IVD tripartite
structure functions in an integrated biophysical manner, with
the hydrogel-like NP acting to resist compression of the spine,
while the fibrous design of the AF permits it to resist tension
and simultaneously retain and support the NP during spinal
loading. The endplates function to hydraulically encase the
NP and AF above and below, as well as providing limited
access to nutrients and structural linkage to the adjacent
vertebral bodies (Sivakamasundari and Lufkin, 2013). Molecular
genetic analysis in mice indicates that the NP is derived
from the notochord, a structure that is laid down by the
retreating node along the rostrocaudal axis during gastrulation
(reviewed in Lawson and Harfe, 2015). In contrast, the AF,
cartilage endplates, and vertebral bodies are all derived from
the sclerotome portion of the somite (Sivakamasundari et al.,
2017). The forkhead-related protein transcription factors Foxa1
and Foxa2 appear to play a critical role in the transition
of notochordal cells to NP cells, as in their absence the
NP fails to form (Maier et al., 2013). Likewise, the paired-
domain containing transcription factors Pax1 and Pax9 are
critical for formation of the AF from the sclerotome, where it
has been shown that they are connected to the chondrogenic
transcription factors Sox5 and Sox6 through a negative
feedback loop. Pax1 and Pax9 appear to mediated their effect
in part via modulation of the BMP and TGF-B pathways
(Sivakamasundari et al., 2017).
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FIGURE 1 | Anatomical structure of the lumbar spine and intervertebral
discs. (A) Lateral view of three adjacent human vertebrae (VB) with two
intervening intervertebral discs (IVD). The VB attaches to the IVD through the
cartilage end plates (CEP). The spinal nerve (SN) roots exiting the spinal cord
are indicated, as well as the transvers processes (TP) that connect the VB to
the spinous process (not visible). With increased age the IVD becomes thinner
in part due to fluid loss from the extracellular spaces. This can result in the
formation of bone spurs (osteophytes), which in turn can impinge on the spinal
nerve roots causing severe pain. (B) Rostral (superior) view of the intervertebral
disc (IVD) with the CEP removed to allow better visualization of the internal
IVD. The concentric circles of lamellae (L) that make up the annulus fibrosus
(AF) are indicated with arrows. The centrally located gelatinous nucleus
pulposus (NP) is indicated and is surrounded by the AF. The caudally (inferior)
located vertebral body (VB) and transverse process (TP) are indicated, as well
as the location of the spinal cord (SC).
TREATING IVD DISEASE WITH MSCS
Mesenchymal stem cells (MSCs) have been studied as a potential
source material for treating cartilaginous skeletogenic defects,
andwith regards to the IVD themajority have focused onNP cells
(reviewed in Sivakamasundari and Lufkin, 2012, 2013). The bulk
of these studies resulted in cells that were closer in phenotype to
chondrocytes, rather than NP cells. Chondrogenic differentiated
MSCs are unlikely to be the best choice for repair of a damaged
disc. Injection of such cells in the NP does not result in the
appropriate hydrogel matrix characteristic of the NP, but instead
results in the generation of hyaline cartilage. Notochordal cells
have been investigated as a substrate to coax MSCs toward an NP
phenotype (Purmessur et al., 2011). Micromass cultured human
MSCs when exposed to notochord cell conditioned medium
showed an increase in glycosaminoglycan (GAG) and an up-
regulation of SOX9 and COLII gene expression (Purmessur et al.,
2011) hence the identification and optimization of the soluble
factors produced by notochordal cells could provide a supporting
strategy for directing MSCs to a NP phenotype. Thus being able
to coax MSCs toward an AF or NP fate will be crucial to ensure
future effective disc repair. Progress in this direction has been
hampered in part by a poor consensus on identifying markers
which clearly distinguish between NP and AF cells (Thorpe et al.,
2016). In fact some studies suggest that both the NP and AF
may be composed of a heterogeneous cell population (Van Den
Akker et al., 2014, 2016; Thorpe et al., 2016; Kraus et al., 2017).
Nevertheless, such studies have served as a jumping off spot to
adjust the in vitro cell culture conditions to more directly obtain
AF or NP cells from multipotent stem cells (Hofer and Tuan,
2016).
DIRECTING STEM CELLS TOWARD AN NP
OR AF LINEAGE
The majority of studies on differentiating mesenchymal stem
cells (MSCs) to an IVD cell type have focused on the NP cell
phenotype. In contrast, AF cells have received less attention,
although repair of the AF would be of great utility in reversing
the effects of herniations and tears which result in prolapsed
or herniated “slipped” discs. Recent animal studies suggest that
BMSCs could be an effective treatment to a damaged AF (Li
et al., 2016). The AF is comprised of water and an intricate
concentric layering of crisscross oriented elastic collagen fibers
known as lamellae. The crisscross orientation of the lamellae
give the AF greater strength not unlike the concentric belts
in an automobile tire. The AF can be subdivided into two
parts, the inner AF (IAF) and the outer AF (OAF). The IAF is
cartilaginous during embryogenesis and expresses large amounts
of Collagen II, whereas the OAF is more fibrous and expresses a
greater amount of Collagen I (Sivakamasundari et al., 2017). This
demarcation between IAF and OAF become less pronounced
at later stages of development and in the adult. (Hayes and
Ralphs, 2011). The fact that the entire spine research field has
so far been unsuccessful in generating true AF and NP cells
from MSCs suggests that they might not be the ideal starting
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material despite their relative ease of isolation and autologous
nature. Their stem cell potency as described abovemay be limited
such that they cannot adopt either the AF or NP identity or
important clues from the extracellular matrix are missing. It
is for that reason that work with hESCs remains important,
and resulting differentiation protocols are likely transferable to
autologous induced pluripotent stem cells (iPSCs).
SUCCESSFUL STEM CELL TRIALS IN
ANIMALS
Animal studies suggest that the IVD contains a resident stem
cell population (Shi et al., 2015; Kraus et al., 2017), however this
work was performed in rodents and bovine so it is unclear if
the same cell populations will be found in humans. Interestingly,
the canine breed Dachshund is commonly aﬄicted with disc
degeneration and disc herniation in a manner similar to humans
(Hoffman and Dow, 2016). Like humans, aﬄicted canines can
show back pain, impaired movement, or near paralysis. In several
studies using mesenchymal stem cells injected into affected
discs, treated canines showed improvement, including reduced
pain, ataxia, improved reflexes, and neurologic-locomotory
recovery although surprisingly there did not appear to be
any ultrastructural changes as monitored by MRI (reviewed in
Hoffman and Dow, 2016). This underscores the utility of using
an animal model (canine or bovine Kraus et al., 2017) which
are more similar to human and also indicates that the criteria
for stem cell mediated clinical success of disc disease might
be focused on alleviation of symptoms and recovery of normal
activity rather than ultrastructural changes in the spine as assayed
by MRI.
STEM CELLS IN HUMAN CLINICAL TRIALS
FOR IVD DISEASE
In a recent controlled study of 24 patients with chronic low back
pain, 12 received a transplantation of allogeneic mesenchymal
bone marrow cells via intradiscal injection (Noriega et al.,
2016). Five of the treated patients (∼40%) displayed a quick
and significant improvement in pain relief suggesting that this
simple, non-surgical procedure can provide pain relief to a
certain percentage of those suffering from chronic low back pain
(Noriega et al., 2016). In another recent independent study on
humans (Elabd et al., 2016), five patients who presented with
degenerated discs had bone marrow mesenchymal stem cells
removed and cultured in vitro under hypoxic conditions, which is
the normal state of the IVD. The patients subsequently received
intra-discal injections of their own (autologous) hypoxic cultured
cells. Follow up studies after several years including MRI showed
no aberrant growths (tumors) or abnormalities and the patients
reported improvements in both mobility and strength (Elabd
et al., 2016). These results suggest the feasibility and safety of this
approach. Future work should possibly focus on a randomized,
controlled, double blind study with a larger number of patients.
The U.S. National Institutes of Health has a searchable
database for clinical trials (https://clinicaltrials.gov). At the time
of this writing a search identified 36 studies that have been
registered for stem cell treatments of defective or diseased
intervertebral discs. Eight of these studies are currently recruiting
patients. One ongoing trial with an estimated enrollment of 360
patients is being directed by Mesoblast, Ltd (Mesoblast, 2016).
The company which is based in Melbourne, Australia and New
York, NY features proprietary allogeneic mesenchymal adult
stem cells (MLCs) which are purported to be found adjacent
to blood vessels. Using monoclonal antibodies they are able to
isolate from them mesenchymal precursor cells (MPCs) that
are subsequently expanded in culture without differentiation.
Apparently MSCs can be derived from MPCs in cell culture
following density gradient separation and adherence to tissue
culture plastic ware, a characteristic of stem cells. One line of
MPCs is referred to as Rexlemestrocel-L and it will be used in the
clinical trial (Mesoblast, 2016) which has a projected completion
date in 2020. Based upon the above-described successes with
intra-discal injections of MSCs, one could hope for a favorable
outcome.
WILL iPSCs PLAY A SIGNIFICANT ROLE IN
IVD REGENERATION
Induced pluripotent stem cells (iPSCs) either derived from the
patient needing treatment (autologous) or obtained from a cell
bank using a human leukocyte antigen (HLA) matched line
both hold great promise as approaches in regenerative medicine.
However, it appears that the former strategy is very time
consuming and quite costly as extensive quality control (such as
entire genome sequencing) needs to be performed on each of the
individual patient-specific iPSC lines owing to the elevated risk
of generating random mutations, which could possibly lead to
tumor formation during the iPSC generation protocol (Kamao
et al., 2014). Homozygous HLA matched iPSC quality tested,
banked and clinically safe cell lines from healthy donors (like
those found at the CiRA Center, Kyoto University, Japan) also
hold much promise for stem cell based therapies (Sugita et al.,
2016; Takahashi and Yamanaka, 2016), but the current limited
number of lines available makes this an option for only a small
percent of the world’s population (Karagiannis and Eto, 2016;
Sakurai et al., 2016). In a recent interview, Shinya Yamanaka,
who developed the strategy for iPSC generation (Takahashi and
Yamanaka, 2006, 2016) suggested that iPSCs would likely only
be useful for treating approximately nine human diseases (spinal
cord injury, joint disorders, Parkinson’s, specific blood disorders,
heart and liver failure, retinal and corneal diseases, and diabetes)
over the next decade or so, and IVD-related diseases were not
among them (Ravven, 2017). That is not to say that at some point
in the future iPSCs will not be utilized to treat degenerative disc
diseases or other IVD-related pathologies, but rather it does not
appear to be on the immediate horizon.
CONCLUSION
Important advances in regenerativemedicine are at our doorsteps
for the treatment of degenerative diseases that emerge with
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an increasingly longer life span, eventually enabling safe
replacement of failing body parts, such as degenerated IVDs.
All cells of a mature organism have once shared the totipotent
origin of the 1-cell zygote. MSCs are just one type of pluripotency
restricted differentiation product thereof generated through the
concerted interaction of complex transcription factor networks
during development. While the numbers of clinics and private
practices offering MSC-based stem cell treatments for various
degenerative illnesses, including degenerative disc disease, are
on the rise, it remains important to understand the precise
fate and contribution of these cells following their use in a
therapeutic context and as such, promote a safer outcome
for regenerative medicine based approaches to degenerative
diseases.
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